- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.07. | Vertex Pharmaceuticals' cystic fibrosis therapy Alyftrek granted EC approval | ||
| 09.07. | Biogen initiates phase 3 study of felzartamab in kidney disease patients | ||
| 09.07. | Sepsis and the impact of antibiotic resistance | ||
| 08.07. | EC approves Jazz Pharmaceuticals' Ziihera for advanced biliary tract cancer | ||
| 08.07. | Moderna shares positive phase 3 results for mRNA flu vaccine candidate | ||
| 08.07. | Cameras on… | ||
| 07.07. | Regeneron's Lynozyfic granted FDA accelerated approval to treat multiple myeloma | ||
| 07.07. | The Considered appoints Tina Bertolini as chief client services officer | ||
| 07.07. | Alzheimer's disease - the silent pandemic and the positive impact of AI | ||
| 04.07. | Communiqué 2025: celebrating excellence in healthcare communications | ||
| 04.07. | UK government publishes 10 Year Health Plan for England to 'reinvent' NHS | ||
| 04.07. | Beyond the badge: communicating the business case for DEI | ||
| 03.07. | AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition | ||
| 03.07. | Avalere Health appoints Saiqa Khan as head of growth | ||
| 03.07. | ASCO 2025 - bringing a sense of urgency to the war against cancer | ||
| 02.07. | CHMP recommends tablet formulation of BeOne's targeted cancer drug Brukinsa | ||
| 02.07. | The Considered appoints Rob Fuller as chief strategy officer | ||
| 02.07. | Traitorous doubts | ||
| 01.07. | UCB shares promising results for fenfluramine in ultra-rare form of epilepsy | ||
| 01.07. | Avalere Health appoints Jocelyn Crouch as head of brand strategy | ||
| 01.07. | Why tariffs could fuel a new era of domestic pharma manufacturing | ||
| 30.06. | FDA approves Sobi's Gamifant to treat severe inflammatory arthritis complication | ||
| 30.06. | Inizio Evoke appoints Kelly Cusumano as executive vice president, growth and client innovation | ||
| 30.06. | DCODE: your gateway to accelerating local innovation adoption in the UK | ||
| 27.06. | Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .